| Summary: | Arief Kartasasmita,1 Ohisa Harley2 1Departement of Ophthalmology, Universitas Padjadjaran/Cicendo Eye Hospital, Bandung, Indonesia; 2Netra Eye Hospital, Bandung, IndonesiaCorrespondence: Arief KartasasmitaDepartment of Ophthalmology, Universitas Padjadjaran, Jl. Cicendo No 4, Bandung 40141, IndonesiaTel +62 22 4231280Email a.kartasasmita@unpad.ac.idObjective: To evaluate the difference in intravitreal bevacizumab (IVB) injection timing as adjuvant therapy to panretinal photocoagulation in patients with diabetic retinopathy combined with diabetic macular edema.Methods: This was a retrospective nonrandomized study. Forty eyes with severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR) were divided into two groups; the IVB injection prior to, or after, panretinal photocoagulation. Changes in central macular thickness between the two groups were measured.Results: There was no significant difference in change in central macular thickness between two groups after treatment (p=0.66), neither in eyes with severe NPDR groups (p=0.48) nor eyes with PDR (p=0.82).Conclusion: IVB injection after panretinal photocoagulation gives insignificant difference in changes in central macular thickness with injection prior to laser treatment in patients with diabetic retinopathy combined with diabetic macular edema.Keywords: diabetic retinopathy, diabetic macular edema, bevacizumab, panretinal photocoagulation
|
|---|